Patents by Inventor Emyr Lloyd-Evans

Emyr Lloyd-Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Products for Treating the JNCL Disease
    Publication number: 20230321064
    Abstract: The present invention relates to a product containing Miglustat alone, or to a combination product containing parenteral Trehalose and oral Miglustat, for treating lysosomal diseases such as the CLN3 disease.
    Type: Application
    Filed: July 30, 2021
    Publication date: October 12, 2023
    Inventors: Danielle Kerkovich, Helen Waller-Evans, Emyr Lloyd-Evans, Abdallah Amawi, Parisa Lofti, Marco Sardiello
  • Phosphorodiamidates and other phosphorus derivatives of fingolimod and related S1P receptor modulators
    Patent number: 11078221
    Abstract: Compounds of general formula (I): (Formula I)) wherein R1, Q, R3, R4, R5, R6, R7 and Ar1 are as defined herein are inhibitors of class I histone deacetylases and are of use in the treatment of lysosomal storage disorders, especially Niemann-Pick type C disease, as well as other lysosomal storage disorders, defective autophagy, accumulation of free cholesterol and mycobacterial diseases.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: August 3, 2021
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD
    Inventors: Emyr Lloyd-Evans, Fabrizio Pertusati, Edward James, Emily Maguire, Christopher McGuigan
  • PHOSPHORODIAMIDATES AND OTHER PHOSPHORUS DERIVATIVES OF FINGOLIMOD AND RELATED S1 P RECEPTOR MODULATORS
    Publication number: 20200255460
    Abstract: Compounds of general formula (I): (Formula I)) wherein R1, Q, R3, R4, R5, R6, R7 and Ar1 are as defined herein are inhibitors of class I histone deacetylases and are of use in the treatment of lysosomal storage disorders, especially Niemann-Pick type C disease, as well as other lysosomal storage disorders, defective autophagy, accumulation of free cholesterol and mycobacterial diseases.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Inventors: Emyr Lloyd-Evans, Fabrizio Pertusati, Edward James, Emily Maguire, Christopher McGuigan
  • TREATMENT OF MYCOBACTERIAL INFECTION
    Publication number: 20180125796
    Abstract: The invention provides a combination comprising a SERCA antagonist and an inhibitor of glycosphingolipid biosynthesis, for use in the treatment of an infection by a pathogenic mycobacterium. The combination may for instance be used to treat tuberculosis.
    Type: Application
    Filed: January 7, 2016
    Publication date: May 10, 2018
    Inventors: Frances Mary Platt, Nick Platt, Paul Fineran, Edith Sim, Emyr Lloyd-Evans, Nathan Lack
  • Substrate reduction therapy
    Patent number: 9428541
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 30, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Chancellor, Masters, and Scholars of the University of Oxford
    Inventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • SUBSTRATE REDUCTION THERAPY
    Publication number: 20140080769
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicants: The Chancellor, Masters and Scholars of the University of Oxford, The Government of the United States of America, as represented by the Secretary, Department of Healt
    Inventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • Substrate reduction therapy
    Patent number: 8557844
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: October 15, 2013
    Assignees: The Chancellor, Masters and Scholars of the University of Oxford, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • SUBSTRATE REDUCTION THERAPY
    Publication number: 20100204162
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Application
    Filed: June 26, 2008
    Publication date: August 12, 2010
    Inventors: Mary Frances Platt, Emyr Lloyd-Evans, Forbes Dennison Porter